MARKET

ATYR

ATYR

Atyr Pharma Inc
NASDAQ
4.080
-0.910
-18.24%
After Hours: 4.080 0 0.00% 19:30 11/18 EST
OPEN
4.980
PREV CLOSE
4.990
HIGH
5.07
LOW
4.080
VOLUME
117.95K
TURNOVER
--
52 WEEK HIGH
44.40
52 WEEK LOW
4.068
MARKET CAP
10.40M
P/E (TTM)
-0.1877
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATYR last week (1109-1113)?
Weekly Report · 2d ago
Weekly Report: what happened at ATYR last week (1102-1106)?
Weekly Report · 11/09 09:09
aTyr Pharma Files Prospectus for Potential Stock Sales
TipRanks · 11/06 21:32
aTyr Pharma Files ~$80M At-The-Market Offering To Sell Common Stock Through Jefferies
Benzinga · 11/06 21:14
aTyr Pharma downgraded to Hold from Buy at Freedom Broker
TipRanks · 11/06 20:30
Analysts Have Conflicting Sentiments on These Healthcare Companies: CytomX Therapeutics (CTMX), Rezolute (RZLT) and aTyr Pharma (ATYR)
TipRanks · 11/06 19:40
aTyr Pharma Is Maintained at Sector Perform by RBC Capital
Dow Jones · 11/06 19:35
aTyr Pharma Price Target Cut to $6.00/Share From $40.00 by RBC Capital
Dow Jones · 11/06 19:35
More
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

Webull offers aTyr Pharma Inc stock information, including NASDAQ: ATYR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATYR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATYR stock methods without spending real money on the virtual paper trading platform.